A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge.

Autor: Koopman G; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands. koopman@bprc.nl., Amacker M; Mymetics SA, 4 Route de La Corniche, 1066, Epalinges, Switzerland.; Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, 3008, Bern, Switzerland., Stegmann T; Mymetics BV, JH Oortweg 21, 2333 CH, Leiden, The Netherlands., Verschoor EJ; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Verstrepen BE; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Bhoelan F; Mymetics BV, JH Oortweg 21, 2333 CH, Leiden, The Netherlands., Bemelman D; Mymetics BV, JH Oortweg 21, 2333 CH, Leiden, The Netherlands., Böszörményi KP; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Fagrouch Z; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Kiemenyi-Kayere G; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Mortier D; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Verel DE; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Niphuis H; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Acar RF; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Kondova I; Animal Science Department, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Kap YS; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Bogers WMJM; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Mooij P; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands., Fleury S; Mymetics SA, 4 Route de La Corniche, 1066, Epalinges, Switzerland. sylvain.fleury@mymetics.com.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Mar 28; Vol. 13 (1), pp. 5074. Date of Electronic Publication: 2023 Mar 28.
DOI: 10.1038/s41598-023-31818-y
Abstrakt: Influenza virosomes serve as antigen delivery vehicles and pre-existing immunity toward influenza improves the immune responses toward antigens. Here, vaccine efficacy was evaluated in non-human primates with a COVID-19 virosome-based vaccine containing a low dose of RBD protein (15 µg) and the adjuvant 3M-052 (1 µg), displayed together on virosomes. Vaccinated animals (n = 6) received two intramuscular administrations at week 0 and 4 and challenged with SARS-CoV-2 at week 8, together with unvaccinated control animals (n = 4). The vaccine was safe and well tolerated and serum RBD IgG antibodies were induced in all animals and in the nasal washes and bronchoalveolar lavages in the three youngest animals. All control animals became strongly sgRNA positive in BAL, while all vaccinated animals were protected, although the oldest vaccinated animal (V1) was transiently weakly positive. The three youngest animals had also no detectable sgRNA in nasal wash and throat. Cross-strain serum neutralizing antibodies toward Wuhan-like, Alpha, Beta, and Delta viruses were observed in animals with the highest serum titers. Pro-inflammatory cytokines IL-8, CXCL-10 and IL-6 were increased in BALs of infected control animals but not in vaccinated animals. Virosomes-RBD/3M-052 prevented severe SARS-CoV-2, as shown by a lower total lung inflammatory pathology score than control animals.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje